

Colleen Badgley

Partner



cbadgley@cooley.com

+1 206 452 8789

Seattle

Emerging Companies
Mergers and Acquisitions
Venture Capital
Capital Markets
Life Sciences and Healthcare
Technology
Digital Health
Wellness
Impact Investing and Mission-Driven Enterprises

Colleen represents emerging high-growth companies throughout their life cycle, with a focus on all aspects of emerging company development, including corporate formation, venture capital financings, corporate spinouts and restructurings, mergers and acquisitions, and capital markets transactions. She also has experience representing venture capital and angel investors in their investment transactions. Since 2021, Colleen has handled VC financings with an aggregate deal value of more than \$3.5 billion. Colleen is counsel to companies and their investors in a range of high-growth industries, including the life sciences, digital health, software, technology and consumer sectors.

Colleen's private company clients have included AnySignal, Archon Biosciences, Arzeda, Donuts (acquired by Abry), Nest Healthcare, New Engen (acquired by Insignia Capital), Nuance Labs, Outpace Biosciences, Parse Biosciences (acquired by QIAGEN), Polyarc, PVP Biologics (acquired by Takeda Pharmaceuticals), Scala.ai, Syndio, Talking Rain, Tasso and Vilya. Her public company clients have included Accolade, Alder BioPharmaceuticals (acquired by Lundbeck), Bolt Biotherapeutics, Etsy, Instacart and Instructure (acquired by Thoma Bravo). VC firms and investment banks Colleen has represented include 8VC, Andreessen Horowitz (a16z), ARCH Venture Partners, Barclays Capital, Cowen and Company, General Catalyst, Goldman Sachs, Jefferies, Madrona Venture Group, New Enterprise Associates and Redpoint Ventures.

Colleen's recent representative transactions include advising:

- A16z in its investment in Braveheart Bio's \$185 million Series A financing
- Accolade in its \$220 million initial public offering (IPO) and \$221 million secondary public offering
- AnySignal in its \$24 million Series A financing
- Aradigm in its \$20 million Series A financing
- ARCH Venture Partners in its investment in Kardigan's \$254 million Series B financing
- ARCH Venture Partners in its investment in Xaira Therapeutics' \$1 billion Series A financing
- Arzeda in its \$33 million Series B financing
- Bolt Biotherapeutics in its \$264 million IPO
- Bonum Therapeutics in its spinout from Good Therapeutics and its \$93 million Series A financing
- Decagon AI in its \$35 million Series A financing
- Form Bio in its \$30 million Series A financing
- General Catalyst in its investment in Eleanor Health's \$50 million Series C financing

- Good Therapeutics in its sale to Roche for \$250 million upfront
- Instacart in its \$660 million IPO
- Kimia Therapeutics in its spinout from Carmot Therapeutics and \$55 million Series A financing
- Knapsack in its \$10 million Series A financing
- Nuance Labs in its \$10 million Series Seed financing
- Outpace Bio in its \$144 million Series B financing
- Parse Biosciences in its sale to QIAGEN for \$280 million
- Petra Pharma in its sale to Eli Lilly for an undisclosed amount
- Poppi in its \$1.95 billion sale to PepsiCo
- Vilya in its \$71 million Series A financing
- Zephyr AI in its acquisition of Aster Insights

While attending the University of Michigan Law School, Colleen served as an international fellow at the World Intellectual Property Organization in Geneva, Switzerland, and was a member of the Zell Entrepreneurship Clinic

Education

University of Michigan Law School JD, magna cum laude, 2014

Loyola Marymount University BA, Psychology, magna cum laude, 2011

Admissions & Credentials

Washington